Coagulation Studies on Separated Fibrinogen Break-down Products

Summary

Fibrinogen break-down products obtained by plasmindigestion in vitro (human material) are separated by column chromatography on DEAE-Sephadex. The various fractions are defined immunologically and by means of disc acrylamide electrophoresis. A plasminsensitive and a plasminresistant fraction exhibiting E- and D-antigenic properties respectively significantly inhibit some early stages of bloodcoagulation, when present in the final concentration of 5–25 mg%. Some other labile intermediates were less active. No significant prolongation of plasma thrombin time is obtained using separated D- or E-fractions even in final concentration of 100 mg%.

• References

• 1 Alkjaersig N.A, Fletscher A.P, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. II. The significance, mechanism and consequences of defective fibrinpolymerization. J. clin. Invest 1962; 41: 917-934
• 2 Fletcher A.P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. clin. Invest 1962; 41: 896-916
• 3 Fletcher A.P, Alkjaersig N, Fischer S, Sherry S. The proteolysis of fibrinogen by plasmin. The identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J. Lab. clin. Med 1966; 68: 780-802
• 4 Gormsen J, Sivertzen U. The effect of sulfhydrylinhibitors and glycine derivatives on fibrin polymerization and physical strength of fibrin in plasma. Thrombos. Diathes. heamorrh. (Stuttg.) 1964; 6: 454-467
• 5 Gormsen J.B. Laursen-Fibrinogen breakdown products and clotting parameters. Thrombos. Diathes. haemorrh 1967; 17: 467-482
• 6 Hirsh J, Fletcher A.P, Sherry S. Effect of fibrin and fibrinogen proteolysis products on clot physical properties. Amer. J. Physiol 1965; 209: 415-424
• 7 Larrieu M.J, Mardow V.J, Inceman S. Effects of fibrinogen degradation products on platelets and coagulation. Diffuse Intravascular Coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 251: 226
• 8 Latałło Z.S, Budzynski A.Z, Lipinski B, Kowalski E. Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmindigested fibrinogen. Nature (Lond.) 1964; 203: 1184-1185
• 9 Laursen B. Fibrinogen and fibrin breakdown products demonstrated by immunodiffusion and Immunoelectrophoresis.(In preparation.)
• 10 Niewiarowski S, Batallo Z.S, Stachurska J. Apparition d’une inhibiteur de la thromboplastinoformation au cours de la protéolyse du fibrinogène. Rev hémat 1959; 14: 118-128
• 11 Nussenzweig V, Seligmann M, Grabar P. Les produits de degradation du fibrinogène humain par la plasmine. II. Etude immunologique : Mise en évidence d’anticorps antifibrinogene natif possédant des spécificites différentes. Ann Inst. Pasteur 1961; 100: 490-508
• 12 Ouchterlony Ö. Antigen-antibody reactions in gel Arkiv. Kemi Mineral Geol 1948; 26B: 1
• 13 Triantophyllopoulos D.C, Triantophyllopoulos E. Evidence of antithrombic activity of the anticoagulant fraction of incubated fibrinogen. Brit. J. Haemat 1966; 12: 145-151
• 14 Triantophyllopoulos E.D.G. Triantophyllopoulos : Variability of the anticoagulant fraction of incubated fibrinogen. Amer. J. Physiol 1965; 208: 521-527
• 15 Wadsworth L, Hansson L.Ä. Comparative analysis of immune-electrophoretic precipitates employing a modified immune-electrophoretic technique. Intern. Arch. Allergy 1960; 17: 165-177